Newron Pharmaceuticals SpA

NWRN

Company Profile

  • Business description

    Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.

  • Contact

    Via Antonio Meucci 3
    Bresso
    Milan20091
    ITA

    T: +39 26103461

    https://www.newron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    23

Stocks News & Analysis

stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.
stocks

AI stocks winners, laggards and losers for 2025

AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks

12 picks for an income portfolio - Q4 2025 update

Eighteen months in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,045.9027.80-0.31%
CAC 408,325.1891.261.11%
DAX 4025,261.64134.180.53%
Dow JONES (US)49,504.07237.960.48%
FTSE 10010,108.3263.630.63%
HKSE26,231.7982.480.32%
NASDAQ23,671.35191.330.81%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,696.2520.61-0.15%
S&P 5006,966.2844.820.65%
S&P/ASX 2008,717.8029.10-0.33%
SSE Composite Index4,120.4337.450.92%

Market Movers